AgeX Therapeutics and Lineage Cell Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells – Yahoo…
By daniellenierenberg
AgeX Therapeutics, Inc. (NYSE American: AGE) and Lineage Cell Therapeutics, Inc. (NYSE American and TASE LCTX), announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,501,723, entitled "Methods of Reprogramming Animal Somatic Cells" covering what is commonly designated "induced Pluripotent Stem (iPS) cells. The issued claims include methods to manufacture pluripotent cells capable of becoming any cell in the body. The patent has an early priority date, having been filed before the first scientific publication of Shinya Yamanaka, for which he won the Nobel Prize for Physiology or Medicine in 2012.
"This patent broadly describes multiple techniques for reprogramming cells of the body back to the all-powerful stem cell state," said Dr. Michael D. West, CEO of AgeX and first inventor on the patent. "Perhaps more significantly, it includes certain factors that address some of the difficulties currently encountered with iPS cells. It also reflects the foundational work our scientists have undertaken to apply reprogramming technology to age-reversal, specifically, induced Tissue Regeneration (iTR) which is currently a focus of AgeX product development." A video describing the significance of the patent in AgeXs product development is available on the AgeX website.
"The issuance of this patent highlights Lineages dominant position in the field of cell therapy," stated Brian M. Culley, CEO of Lineage. "Our efforts to develop new treatments rely on well-characterized and NIH-approved human cell lines. These lines are not genetically manipulated, which avoids the safety concerns associated with genetic aberrations arising from the creation of iPS cells. We believe the Lineage cell lines provide the safest option for our current clinical-stage programs, particularly in immune-privileged anatomical sites such as the eye (OpRegen for the treatment of dry AMD) and spinal cord (OPC1, for the treatment of spinal cord injury). However, the vast intellectual property estate which underlies our cell therapy platform has never been limited to these particular cell lines. As one example, this newly-issued patent provides us with proprietary methods for producing induced pluripotent stem cells, or, as it was practiced by us prior to Yamanaka, Analytical Reprogramming Technology (ART). In certain settings, an ART/iPS approach might offer important advantages, such as for an autologous treatment or when the selection of preferential attributes from a series of iPS lines is desirable. Questions as to which stem cell technology is preferred ultimately will be answered by clinical safety and efficacy and likely will be indication-specific, so we believe it is in the best interest of our shareholders to generate patented technology which enables us to pursue programs in either or both formats which we believe will ensure the highest probability of success."
Induced Pluripotent Stem Cells (iPS) are typically derived from adult skin or blood cells which have been "reprogrammed" or "induced" to retrace their developmental age and regain the potential to form all of the young cell and tissue types of the body. In 2010 inventors of the -723 patent issued today demonstrated that this reversal of developmental aging even extended to the telomere clock of cell aging. This reprogramming technology provides an alternate source of starting material for the manufacture of potentially any type of human cell needed for therapeutic purposes. Because iPSCs can be derived directly from adult tissues, they can be used to generate pluripotent cells from patients with known genetic abnormalities for drug discovery or as an alternative source of cell types for regenerative therapies.
U.S. Patent No. 10,501,723, entitled "Methods of Reprogramming Animal Somatic Cells" was assigned to Advanced Cell Technology of Marlborough, Massachusetts (now Astellas Institute for Regenerative Medicine) and licensed to Lineage and sublicensed to AgeX Therapeutics for defined fields of use. Inventors of the patent include Michael D. West, CEO of AgeX and previous CEO of Advanced Cell Technology, Karen B. Chapman, Ph.D., and Roy Geoffrey Sargent, Ph.D.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.
Story continues
For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineages programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineages clinical assets include (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. Lineage is also evaluating potential partnership opportunities for Renevia, a facial aesthetics product that was recently granted a Conformit Europenne (CE) Mark. For more information, please visit http://www.lineagecell.com or follow the Company on Twitter @LineageCell.
Forward-Looking Statements
Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates" should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the "Risk Factors" section of AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005435/en/
Contacts
Media Contact for AgeX:Bill Douglass Gotham Communications, LLCbill@gothamcomm.com (646) 504-0890
Continue reading here:
AgeX Therapeutics and Lineage Cell Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells - Yahoo...
- 001 Ying Liu discusses IPS cell therapy for ALS [Last Updated On: August 6th, 2011] [Originally Added On: August 6th, 2011]
- 002 Jeanne Loring talks about stem cells, part 2 [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- 003 Embryonic Stem Cells From Skin: Making Old Cells Young [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- 004 IPs cells Part3 [Last Updated On: September 6th, 2011] [Originally Added On: September 6th, 2011]
- 005 IPs cells Part 2 [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- 006 A Century of Stem Cells - Johns Hopkins Medicine [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- 007 Stem Cell Implications for ALS (Amyotrophic Lateral Sclerosis) [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- 008 Myelin Repair Foundation on Stem Cell Research [Last Updated On: September 9th, 2011] [Originally Added On: September 9th, 2011]
- 009 IPs Cells Part 4 [Last Updated On: September 11th, 2011] [Originally Added On: September 11th, 2011]
- 010 National Medical Report [Last Updated On: September 13th, 2011] [Originally Added On: September 13th, 2011]
- 011 IPs cells Part 1 [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- 012 iPS Stem Cell-Based Treatment of Epidermolysis Bullosa [Last Updated On: September 16th, 2011] [Originally Added On: September 16th, 2011]
- 013 Jeanne Loring talks about stem cells, part 1 [Last Updated On: September 16th, 2011] [Originally Added On: September 16th, 2011]
- 014 Kristopher Nazor 2 [Last Updated On: September 16th, 2011] [Originally Added On: September 16th, 2011]
- 015 Andalusian Stem Cell Bank [Last Updated On: September 19th, 2011] [Originally Added On: September 19th, 2011]
- 016 Cellular Reprogramming Stem Cell Domain Name For Sale! - CellularReprogramming.com [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- 017 Dr. Oz to Oprah and Michael J Fox: "The stem cell debate is dead." [Last Updated On: September 22nd, 2011] [Originally Added On: September 22nd, 2011]
- 018 Manning, Owens Try Stem Cell Therapy [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- 019 Jeanne Loring talks about stem cells, part 3 [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- 020 Epidermolysis Bullosa: Corrected iPS Stem Cell-Based Therapy - Video [Last Updated On: October 13th, 2011] [Originally Added On: October 13th, 2011]
- 021 Introduction to Stem Cells - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- 022 Parkinson's Disease: Progress and Promise in Stem Cell Research - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- 023 stem cell research - Video [Last Updated On: December 7th, 2011] [Originally Added On: December 7th, 2011]
- 024 Ian Wilmut discusses stem cell and direct cellular transformation therapy - Video [Last Updated On: December 8th, 2011] [Originally Added On: December 8th, 2011]
- 025 Jeff Bluestone: Immune rejection of stem cell transplants - Video [Last Updated On: December 8th, 2011] [Originally Added On: December 8th, 2011]
- 026 Advances in Stem Cell Research: Shinya Yamanaka - Video [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- 027 2011 Summit: Stem Cells, Reprogramming and Personalized Medicine, Rudolf Jaenisch, MD - Video [Last Updated On: December 14th, 2011] [Originally Added On: December 14th, 2011]
- 028 Parkinson's Disease: Advancing Stem Cell Therapies - 2011 CIRM Grantee Meeting - Video [Last Updated On: January 20th, 2012] [Originally Added On: January 20th, 2012]
- 029 Professor Alan Trounson - World focus on stem cell research - Video [Last Updated On: January 27th, 2012] [Originally Added On: January 27th, 2012]
- 030 Stanford scientists turn skin cells into neural precusors, bypassing stem-cell stage [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- 031 Researchers turn skin cells into neural precusors, bypassing stem-cell stage [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- 032 “Wide-ranging applications for pluripotent stem cells” [Last Updated On: February 2nd, 2012] [Originally Added On: February 2nd, 2012]
- 033 Radiation treatment transforms breast cancer cells into cancer stem cells [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- 034 Radiation Treatment Generates Cancer Stem Cells from Less Aggressive Breast Cancer Cells [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- 035 Radiation treatment generates cancer stem cells from less aggressive breast cancer cells, study suggests [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- 036 Life Technologies Scientist Uma Lakshmipathy presents, "Solving Challenges in the Generation of Induced Pluripotent ... [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- 037 Radiation therapy transforms breast cancer cells into cancer stem cells [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- 038 Research and Markets: Primary and Stem Cells: Gene Transfer Technologies and Applications [Last Updated On: February 15th, 2012] [Originally Added On: February 15th, 2012]
- 039 Horizon in new super-cell elite [Last Updated On: February 16th, 2012] [Originally Added On: February 16th, 2012]
- 040 Presentations at the Society of Toxicology Annual Meeting Demonstrate Superior Predictivity of Cellular Dynamics ... [Last Updated On: March 8th, 2012] [Originally Added On: March 8th, 2012]
- 041 New approach to treating type 1 diabetes? Transforming gut cells into insulin factories [Last Updated On: March 12th, 2012] [Originally Added On: March 12th, 2012]
- 042 Gut cells transformed into insulin factories 'could help to treat type I diabetes' [Last Updated On: March 12th, 2012] [Originally Added On: March 12th, 2012]
- 043 A new approach to treating type I diabetes? Gut cells transformed into insulin factories [Last Updated On: March 12th, 2012] [Originally Added On: March 12th, 2012]
- 044 Columbia Researchers Find Potential Role for Gut Cells in Treating Type I Diabetes [Last Updated On: March 12th, 2012] [Originally Added On: March 12th, 2012]
- 045 Study demonstrates cells can acquire new functions through transcriptional regulatory network [Last Updated On: March 14th, 2012] [Originally Added On: March 14th, 2012]
- 046 Gut Cells Turned To Insulin Factories - New Type l Diabetes Treatment [Last Updated On: March 14th, 2012] [Originally Added On: March 14th, 2012]
- 047 Cellular Dynamics Expands Distribution Agreement with iPS Academia Japan, Inc. to Include Distribution of iCell ... [Last Updated On: March 28th, 2012] [Originally Added On: March 28th, 2012]
- 048 :: 20, Apr 2012 :: IBN DISCOVERS HUMAN NEURAL STEM CELLS WITH TUMOR TARGETING ABILITY – A PROMISING DISCOVERY FOR ... [Last Updated On: April 22nd, 2012] [Originally Added On: April 22nd, 2012]
- 049 Human neural stem cells with tumor targeting ability discovered [Last Updated On: April 22nd, 2012] [Originally Added On: April 22nd, 2012]
- 050 IBN Discovers Human Neural Stem Cells, Promising Discovery For Breast Cancer Therapy [Last Updated On: April 22nd, 2012] [Originally Added On: April 22nd, 2012]
- 051 IBN Discovers Human Neural Stem Cells with Tumor Targeting Ability - A Promising Discovery for Breast Cancer Therapy [Last Updated On: April 22nd, 2012] [Originally Added On: April 22nd, 2012]
- 052 VistaGen Secures Key U.S. Patent Covering Stem Cell Technology Methods Used to Test Drug Candidates for Liver Toxicity [Last Updated On: April 25th, 2012] [Originally Added On: April 25th, 2012]
- 053 Improved adult-derived human stem cells have fewer genetic changes than expected [Last Updated On: May 2nd, 2012] [Originally Added On: May 2nd, 2012]
- 054 Researchers restore neuron function to brains damaged by Huntington's disease [Last Updated On: May 31st, 2012] [Originally Added On: May 31st, 2012]
- 055 Cellular Dynamics Launches MyCell™ Services [Last Updated On: June 7th, 2012] [Originally Added On: June 7th, 2012]
- 056 Fate Therapeutics And BD Biosciences Launch BD™ SMC4 To Improve Cellular Reprogramming And IPS Cell Culture Applications [Last Updated On: June 12th, 2012] [Originally Added On: June 12th, 2012]
- 057 Life Technologies and Cellular Dynamics International Partner for Global Commercialization of Novel Stem Cell ... [Last Updated On: June 13th, 2012] [Originally Added On: June 13th, 2012]
- 058 LIFE Focuses on Stem Cell Research - Analyst Blog [Last Updated On: June 20th, 2012] [Originally Added On: June 20th, 2012]
- 059 International Stem Cell Corp Granted Key Patent for Liver Disease Program [Last Updated On: September 30th, 2012] [Originally Added On: September 30th, 2012]
- 060 NeuroGeneration Recruits Top Scientist To Direct New Division of Biotherapeutics and Drug Discovery In La Jolla, CA [Last Updated On: October 5th, 2012] [Originally Added On: October 5th, 2012]
- 061 FRC Supports Alliance Defending Freedom, Jubilee Campaign Cert Petition to Supreme Court on Stem Cell Funding [Last Updated On: October 11th, 2012] [Originally Added On: October 11th, 2012]
- 062 10/11/2012 10:05 JAPAN Nobel Prize for Yamanaka, scientific research and ethics must go hand in hand [Last Updated On: October 11th, 2012] [Originally Added On: October 11th, 2012]
- 063 Read in [Last Updated On: October 12th, 2012] [Originally Added On: October 12th, 2012]
- 064 Induced pluripotent stem cell - Wikipedia, the free encyclopedia [Last Updated On: November 3rd, 2013] [Originally Added On: November 3rd, 2013]
- 065 What are induced pluripotent stem cells or iPS cells? - Stem Cells ... [Last Updated On: November 3rd, 2013] [Originally Added On: November 3rd, 2013]
- 066 Stem Cell Definitions | California's Stem Cell Agency [Last Updated On: November 3rd, 2013] [Originally Added On: November 3rd, 2013]
- 067 iPSCTherapy.com: Induced Pluripotent Stem Cell therapy Information ... [Last Updated On: November 8th, 2013] [Originally Added On: November 8th, 2013]
- 068 Human muscle stem cell therapy gets help from zebrafish [Last Updated On: November 8th, 2013] [Originally Added On: November 8th, 2013]
- 069 Induced pluripotent stem cell therapy - Wikipedia, the free ... [Last Updated On: November 8th, 2013] [Originally Added On: November 8th, 2013]
- 070 IPS Cell Therapy - Genetherapy [Last Updated On: November 8th, 2013] [Originally Added On: November 8th, 2013]
- 071 MD Supervised Stem Cell Therapy [Last Updated On: November 9th, 2013] [Originally Added On: November 9th, 2013]
- 072 Stem Cell Therapy for Neuromuscular Diseases | InTechOpen [Last Updated On: November 23rd, 2013] [Originally Added On: November 23rd, 2013]
- 073 Combining Stem Cell Therapy with Gene Therapy | Boston ... [Last Updated On: November 25th, 2013] [Originally Added On: November 25th, 2013]
- 074 Biomanufacturing center takes central role in developing stem ... [Last Updated On: December 4th, 2013] [Originally Added On: December 4th, 2013]
- 075 Stem Cell Quick Reference - Learn Genetics [Last Updated On: December 6th, 2013] [Originally Added On: December 6th, 2013]
- 076 Induced Pluripotent Stem Cells (iPS) from Human Skin: Probable ... [Last Updated On: December 6th, 2013] [Originally Added On: December 6th, 2013]
- 077 'Something positive for humankind': Girls lend cells to genetic study [Last Updated On: December 13th, 2013] [Originally Added On: December 13th, 2013]
- 078 Stem cell science: Can two girls help change the face of medicine? [Last Updated On: December 13th, 2013] [Originally Added On: December 13th, 2013]
- 079 Okyanos Heart Institute CEO Matt Feshbach Congratulates Japan’s Legislators On Stem Cell Bill And Global Regulatory ... [Last Updated On: December 13th, 2013] [Originally Added On: December 13th, 2013]
- 080 Stem cells for Parkinson's getting ready for clinic [Last Updated On: December 13th, 2013] [Originally Added On: December 13th, 2013]
